LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day
28.10.2020 08:05:00 CET | LEO Pharma | Press release
BALLERUP, Denmark, October 28, 2020 - LEO Pharma A/S today marked World Psoriasis Day by launching a series of videos featuring patients that outline the everyday challenges of living with psoriasis.
The #everydaypsoriasis videos give personal perspectives on the challenges of living with psoriasis. To accompany the patient videos, LEO Pharma staff from around the world filmed a manifesto during COVID home-working restrictions, outlining their everyday commitment to supporting patients with psoriasis:
WATCH OUR MANIFESTO VIDEO HERE
The #everydaypsoriasis campaign video. More information can be found at www.everydaypsoriasis.com
The LEO Pharma campaign is in support of the annual International Federation of Psoriasis Associations (IFPA) World Psoriasis Day. This annual awareness day is dedicated to people living with psoriasis or psoriatic arthritis and is aimed at spreading information and raising the profile of these debilitating diseases.
October 2020 marks the second year of a three-year ‘Connected, Informed, United’ IFPAtheme, with the theme of ‘Be Informed’ the focus of this year.
Henrik Kyndlev, Director of Global External Communications at LEO Pharma, said: “We’re proud to support IFPA’s important initiative, and are keen to do our part in helping people ‘Be Informed’ about psoriasis this year.”
“Our campaign supports this theme in a very simple but powerful way - namely by bringing attention to some everyday psoriasis stories of real-life patients. After all, psoriasis is not just about a single day, but is an everyday challenge for many patients.”
The #everydaypsoriasis campaign centres around three audio-interviews with psoriasis patients, whose stories are brought to life with short animations depicting the everyday challenges they face.
‘Jane’ talks about how the simple, everyday experience of grocery shopping is a challenge, as she feels people are looking at her skin, and think her psoriasis is contagious. Psoriasis is in fact an auto-immune disease and so is not contagious – one of the key messages IFPA want to focus on in 2020.
Watch Jane’s video: click here
‘Steve’ speaks about the sense of futility he sometimes feels because of the cycle of psoriasis flares, and the feeling of going through a “revolving door”.
Watch Steve’s video: click here
‘Becky’ talks about how having psoriasis as a child affected her confidence, and the ongoing challenge she feels now as a young adult.
Watch Becky’s video: click here
Alexandre Fevre, Vice President of Global Marketing, Psoriasis, at LEO Pharma, said of the campaign, “For many patients, psoriasis goes beyond just being a cosmetic challenge. Nearly 60 percent1 of people with psoriasis say their disease is a large problem in their everyday life.”
“This campaign draws attention to some of the everyday psoriasis challenges and gives a voice to psoriasis patients. We also hope it demonstrates LEO Pharma’s continued commitment to helping people achieve healthy skin.”
“As we say on our campaign website, the encouraging news for many patients is that there are ways to manage the condition. Not just treatments, but lifestyle changes too. If you or someone you know is experiencing #everydaypsoriasis challenges, consider approaching your doctor for advice.”
The #everydaypsoriasis videos can be viewed at www.everydaypsoriasis.com.
About psoriasis
Psoriasis is a chronic, systemic inflammatory disease that primarily affects the skin in 125 million people worldwide.1,2 About 80% of patients are affected by plaque psoriasis, the most common clinical form of psoriasis.2 The symptoms of plaque psoriasis are itchy or painful, scaly, inflamed plaques. Plaques may appear anywhere on the body, but often appear on the scalp, knees, elbows and torso.3 Psoriasis is characterized as mild when less than 3% of the body is affected and moderate to severe when more than 3% of the body is affected.4
References
1. Stern RS, et al. J Investig Dermatol Symp Proc. 2004;9(2):136-9.
2. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-659.
3. Menter A et al. J Am Acad Dermatol 2008;58:826.
4. Armstrong AW et al. JAMA Dermatol. 2013;149(10):1180–1185.
To view this video from www.youtube.com, please give your consent at the top of this page.Our Manifesto Video
Contacts
Henrik Kyndlev
HDTDK@leo-pharma.com
+45 3140 6180
About LEO Pharma
The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma presents new data on delgocitinib cream at EADV 2026 highlighting real-world outcomes in adults and new adolescent data in Chronic Hand Eczema (CHE)1.10.2026 12:00:00 CEST | Pressemeddelelse
Interim results from the German REACHED study provide the first real-world evidence on the effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema (CHE), with 28.6% of patients assessed as clear or almost clear after eight weeks of treatment, from none at baseline.1 New post hoc analyses from the phase 3 DELTA TEEN trial show greater reductions in daily HESD itch and pain scores with delgocitinib cream than with cream vehicle in adolescents aged 12-17 with moderate to severe CHE.2 In an oral presentation, new post hoc analyses from DELTA TEEN show that a higher proportion of adolescents reported no impact on quality of life at Week 16 with delgocitinib cream than with cream vehicle (27.0% vs 0%)3
LEO Pharma presents new tralokinumab data at EADV 2026 highlighting real-world outcomes and quality of life in adults and adolescents with atopic dermatitis (AD) involving high-burden areas1.10.2026 10:30:00 CEST | Pressemeddelelse
New findings from a subgroup analysis of the 12-month TRACE study show that more than 70% of adults whose Atopic Dermatitis (AD) affected multiple high-burden areas – such as the head and neck, hands and feet, or genitals – had reduced involvement of those areas after 12 months of treatment with tralokinumab.1 New pre-specified and post hoc analyses from the phase 3 ADHAND trial show significantly greater improvements in quality of life, daily function and sleep at Week 16 with tralokinumab monotherapy than with placebo in adults with AD and moderate-to-severe hand involvement, with the two treatment groups separating within two weeks.2,3 In a post hoc analysis, adolescents aged 12-17 years treated across the phase 3 ECZTRA 6 trial and its ECZTEND extension, response rates remained high and stable through most of the extension period, and no new safety concerns were identified.5
LEO Pharma to showcase its broadest ever scientific program at EADV 202624.9.2026 09:00:00 CEST | Pressemeddelelse
LEO Pharma will present 28 accepted abstracts at the 2026 European Academy of Dermatology and Venereology Congress, taking place from 30 September to 3 October in Vienna, Austria. The EADV 2026 program reflects the strength and breadth of LEO Pharma’s portfolio, showcasing what’s now and what’s next in medical dermatology with new evidence across nine disease areas, six routes of administration and nine modes of action; including biologic injectables, topical formulations, and covering data across established dermatology brands and new innovation. The program underscores LEO Pharma’s continued commitment to advancing medical dermatology through evidence that addresses both highly prevalent chronic skin diseases and complex or rare, hard-to-treat conditions with significant unmet needs.
LEO Pharma receives positive CHMP opinion recommending Anzupgo® (delgocitinib) cream for adolescents with moderate to severe chronic hand eczema in the EU18.9.2026 10:00:00 CEST | Pressemeddelelse
The Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the use of Anzupgo® (delgocitinib) cream to adolescents aged 12 to 17 years with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or inappropriate. If approved by the European Commission, Anzupgo® would become the first therapy in the EU specifically approved for adolescents with moderate to severe chronic hand eczema, a patient population for whom there are currently no specifically approved treatment options. The positive CHMP opinion is supported by results from DELTA TEEN, a phase 3 trial investigating the efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema.1
LEO Pharma announces FDA acceptance of dersimelagon NDA with Priority Review and closes acquisition from Tanabe Pharma18.9.2026 09:00:00 CEST | Pressemeddelelse
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for dersimelagon for filing and granted it Priority Review, with a Prescription Drug User Fee Act (PDUFA) date expected by the end of February 2027. LEO Pharma has successfully closed the acquisition of dersimelagon from Tanabe Pharma, strengthening its late-stage pipeline and further leveraging its global dermatology platform. Dersimelagon is an investigational, once-daily oral melanocortin 1 receptor (MC1R) agonist for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), two rare genetic skin diseases with significant unmet medical need.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom